About us
  • Founded in 2007 by leading scientists from Sicor Biotech (TEVA Pharmaceuticals) who led the CMC development of Tevagrastim, one of the first biosimilars in the EU
  • Portfolio of 6 cost-efficient biosimilar technologies offered for out-licensing
  • 1 technology already out-licensed for certain markets!
  • Pipeline of 4 biobetter technologies developed using patented ProMER™ platform, that allows extending biopharmaceuticals’ circulation half-life in plasma
  • Focus on wave 3 biosimilar products (with patents running-out after 2020)
  • EU cGMP certification for batch release and analytical testing
  • Access to cGMP manufacturing to supply clinical and commercial needs
  • In-depth know-how in: high-yield expression system development, easy-to-handle up-stream and down-­stream process development, formulation development and comparability studies

 

Key areas of activity:

  • EU GMP release testing – contract based validation and analysis of generics
  • Pharmaceuticals technology transfer: development and transfer of technologies for manufacturing of biosimilars and generics
  • ProMER biopharmaceuticals – development of innovative protein biopharmaceuticals based on proprietary ProMER technology

 

Key capabilities:

Profarma’s  highly experienced, flexible team is capable of creating and developing  technology from gene to protein, including:

  • Expression system development
  • Up-stream processes development
  • Down-­stream process development
  • In-process control and final product analytical development
  • Project management
Contacts
JSC "PROFARMA"


V.A. Graiciuno 6, LT-02241,
Vilnius, Lithuania


Tel. +370 5 2629761,
E-mail: info@profarma.lt